NCT02207218View on ClinicalTrials.gov

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

August 4, 2014

Primary Completion Date

November 10, 2020

Study Completion Date

November 10, 2020

Conditions
Congenital Bleeding DisorderHaemophilia A
Interventions
DRUG

turoctocog alfa

No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.

Trial Locations (2)

1670035

Novo Nordisk Investigational Site, Suginami-ku, Tokyo

167-0035

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT02207218 - To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan | Biotech Hunter | Biotech Hunter